Onivyde® (irinotecan liposome injection) – New indication
February 13, 2024 - Ipsen announced the FDA approval of Onivyde (irinotecan liposome injection), in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma.